drugset / Trial / NCT07323173
A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
Phase 1
Recruiting
112 enrolled
Nanjing Leads Biolabs Co.,Ltd
RenJi Hospital · collabShanghai Public Health Clinical Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2027-12-16
- Completion
- 2027-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LBL-047 | Unknown | — | Subcutaneous |